Candidemia is a bloodstream infection caused by Candida species, often seen in critically ill patients and associated with high mortality. When the fungus spreads beyond the bloodstream, it becomes Disseminated candidiasis, involving organs such as the eyes, brain, and kidneys. Prompt candidemia treatment can mean the difference between recovery and a fatal outcome.
Why Candidemia and Disseminated Infections Demand Immediate Action
Critically ill adults in intensive care units (ICUs) have a 2-4% risk of developing candidemia, with mortality rates approaching 40% if therapy is delayed. The main drivers are central venous catheters, broad‑spectrum antibiotics, and impaired immunity. Once Candida invades deep organs, the clinical picture changes: visual loss from endophthalmitis, renal failure from microabscesses, or meningoencephalitis. Recognising these patterns early allows clinicians to start the right antifungal before organ damage becomes irreversible.
First‑Line Therapy: The Echinocandin Class
The 2023 IDSA (Infectious Diseases Society of America) recommendations place echinocandins as the preferred initial agents for most adult patients with candidemia. They inhibit β‑(1,3)‑D‑glucan synthesis, a cell‑wall component absent in human cells, which translates into excellent efficacy and a low toxicity profile. The three agents available in the UK are:
- Caspofungin - 70mg loading dose then 50mg daily.
- Micafungin - 100mg daily (adjust to 50mg in mild hepatic impairment).
- Anidulafungin - 200mg loading dose then 100mg daily (no dose adjustment needed for liver or kidney).
All three achieve high serum concentrations and penetrate most tissues, making them suitable for both candidemia and disseminated disease. Importantly, they retain activity against Candida auris, an emerging multidrug‑resistant pathogen that has been reported in several UK hospitals.
When Azoles Become the Better Choice
Azole agents, especially fluconazole, remain an option for patients who are clinically stable, have isolates susceptible on testing, and lack prior azole exposure. Fluconazole offers oral bioavailability >90%, allowing step‑down from IV to PO after 48-72hours of negative blood cultures. Typical dosing is 800mg loading, then 400mg daily; higher doses (12mg/kg) may be needed for deep‑tissue infection.
For infections caused by fluconazole‑resistant species (e.g., C. glabrata with dose‑dependent susceptibility or C. krusei), a broader azole such as voriconazole or posaconazole can be considered, but therapeutic drug monitoring is essential because of variable serum levels.
Polyenes: The Old Guard for Severe Cases
When a patient cannot tolerate echinocandins or the organism shows high‑level resistance, amphotericin B (conventional or liposomal) remains a life‑saving option. Liposomal amphotericin B (3-5mg/kg daily) reduces nephrotoxicity compared with the deoxycholate formulation (0.7‑1mg/kg). The drug’s broad spectrum covers virtually all Candida spp., and it achieves excellent fungicidal activity in the bloodstream and deep tissues.
The major drawback is renal impairment, especially in patients already on nephrotoxic meds. Electrolyte monitoring (potassium, magnesium) is mandatory, and dose reductions are advised when serum creatinine rises >2mg/dL.
Combination Therapy and Adjuncts
Evidence for routine combination therapy (e.g., echinocandin+flucytosine) is limited, but it may be justified in end‑organ involvement such as endophthalmitis, where high intra‑ocular concentrations are needed. Flucytosine penetrates the eye and CNS well; dosing is 25mg/kg every 6hours, adjusted for renal function. Close monitoring for bone‑marrow suppression is required.
For patients with central venous catheters, prompt removal is a core component of management. Studies show a 30% reduction in mortality when the catheter is removed within 24hours of diagnosis.
Duration, Monitoring, and De‑escalation
Standard therapy lasts 14days after the first negative blood culture and resolution of signs of infection. In disseminated disease, the duration may extend to 4-6weeks, guided by organ‑specific response (e.g., repeat ophthalmologic exams for endophthalmitis).
Therapeutic drug monitoring is most critical for azoles and flucytosine. Serum trough levels of fluconazole should exceed 4µg/mL; voriconazole troughs target 1‑5µg/mL. Echinocandin levels are not routinely measured but can be checked in patients with severe hepatic impairment.
Practical Decision‑Tree for Choosing Therapy
| Agent | Class | Typical Dose | Key Advantages | Major Toxicities |
|---|---|---|---|---|
| Caspofungin | Echinocandin | 70mg IV loading, then 50mg daily | Broad Candida coverage, low renal impact | Hepatic enzymes ↑, infusion reactions |
| Micafungin | Echinocandin | 100mg IV daily | No dose adjustment for kidney | Mild hepatic ↑, rare hypersensitivity |
| Anidulafungin | Echinocandin | 200mg IV loading, then 100mg daily | Stable pharmacokinetics, no hepatic dose change | Minimal, occasional rash |
| Fluconazole | Azole | 800mg IV/PO loading, then 400mg daily | Oral step‑down, excellent CSF penetration | Hepatotoxicity, QT prolongation |
| Liposomal Amphotericin B | Polyene | 3-5mg/kg IV daily | Broadest spectrum, fungicidal | Nephrotoxicity, electrolyte loss |
Emerging Resistance and Future Directions
Resistance to echinocandins has risen to ~5% in C. glabrata isolates, mainly due to mutations in the FKS genes. When an FKS mutation is identified, clinicians should switch to high‑dose fluconazole (if susceptible) or liposomal amphotericin B.
New agents such as ibrexafungerp (a glucan synthase inhibitor) and rezafungin (a long‑acting echinocandin) are in late‑stage trials and may offer once‑weekly dosing, an advantage for outpatient step‑down.
Related Concepts and Next Topics to Explore
Understanding antifungal susceptibility testing is vital for tailoring therapy. It bridges the gap between empirical choice and targeted treatment. Other closely linked areas include:
- Management of Candida endophthalmitis.
- Infection control measures for Candida auris outbreaks.
- Pharmacokinetic‑pharmacodynamic (PK‑PD) targets for echinocandins.
- Cost‑effectiveness analyses of oral step‑down strategies.
Readers interested in the broader landscape may next explore “Antifungal Stewardship in Critical Care” or “Guidelines for Managing Invasive Fungal Infections in Immunocompromised Hosts.”
Frequently Asked Questions
What is the fastest way to confirm candidemia?
Blood cultures remain the gold standard, but modern laboratories can deliver a positive signal within 24hours using automated detection systems. Adding a β‑D‑glucan assay improves early detection, especially in patients already on antifungal prophylaxis.
When should I switch from an echinocandin to fluconazole?
Switch is appropriate once the isolate is shown susceptible, the patient is clinically stable, and there are no contraindications such as hepatic failure or drug‑drug interactions. A typical timeline is after 48‑72hours of negative cultures and resolution of fever.
Is oral fluconazole as effective as IV therapy for deep‑tissue infection?
For most organ systems, high‑dose oral fluconazole achieves serum levels comparable to IV dosing due to >90% bioavailability. However, for central nervous system or ocular infections, initial IV therapy is recommended until CSF or ocular fluid levels are verified.
How do I manage a patient with Candida auris infection?
C. auris is often resistant to fluconazole and sometimes to echinocandins. Start with an echinocandin (if susceptibility is unknown) and obtain susceptibility results quickly. Infection control measures-contact precautions, dedicated equipment, and environmental cleaning with chlorine‑based products-are essential to prevent spread.
What are the key side effects to watch for with amphotericin B?
Nephrotoxicity is the most common; monitor creatinine daily. Electrolyte disturbances (hypokalemia, hypomagnesemia) occur in up to 30% of patients. Infusion‑related fever and chills are also frequent; pre‑medicating with acetaminophen or antihistamines can help.
When is combination therapy indicated?
Combination (e.g., echinocandin+flucytosine) is reserved for infections where monotherapy fails to achieve adequate tissue levels, such as endophthalmitis, CNS disease, or when the organism shows multidrug resistance. The decision should be guided by susceptibility data and specialist input.
Write a comment